Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|December 3, 2002
DMXAA: an antivascular agent with multiple host responsesBruce C Baguley, Lai Ming ChingJournal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 15, 2008
IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Zachary J Roberts, Lai-Ming Ching, Stefanie N VogelCancer Chemotherapy and Pharmacology|May 3, 2007
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomideFrancisco Chung, Jenny Liu, Lai-Ming Ching, et al.Cancer Chemotherapy and Pharmacology|February 22, 2002
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in miceLiangli Zhao, Philip Kestell, Lai-Ming Ching, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal schedulingLiangli Zhao, Lai-Ming Ching, Philip Kestell, et al.Cancer Letters|February 16, 2010
The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cellsIn Young Hwang, Bruce C Baguley, Lai-Ming Ching, et al.Oncology Research|June 21, 2006
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitorsLiang-Chuan S Wang, See-Tarn Woon, Bruce C Baguley, et al.International Journal of Cancer|April 1, 2005
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeabilityLiangli Zhao, Lai-Ming Ching, Philip Kestell, et al.Immunology and Cell Biology|July 13, 2006
5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapyKate E Matthews, Ian F Hermans, Joanna M Roberts, et al.Cancer Chemotherapy and Pharmacology|April 3, 2004
Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factorFrancisco Chung, Liang-Chuan S Wang, Philip Kestell, et al.Pageof 5